Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Other Accumulated Expenses: 2019-2024

Historic Other Accumulated Expenses for Allogene Therapeutics (ALLO) over the last 1 years, with Dec 2024 value amounting to $1.1 million.

  • Allogene Therapeutics' Other Accumulated Expenses fell 40.74% to $1.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.1 million, marking a year-over-year decrease of 40.74%. This contributed to the annual value of $1.1 million for FY2024, which is 40.74% down from last year.
  • Per Allogene Therapeutics' latest filing, its Other Accumulated Expenses stood at $1.1 million for Q4 2024, which was down 40.74% from $1.8 million recorded in Q4 2023.
  • In the past 5 years, Allogene Therapeutics' Other Accumulated Expenses registered a high of $4.8 million during Q4 2020, and its lowest value of $1.1 million during Q4 2024.
  • Over the past 3 years, Allogene Therapeutics' median Other Accumulated Expenses value was $1.8 million (recorded in 2023), while the average stood at $1.7 million.
  • Per our database at Business Quant, Allogene Therapeutics' Other Accumulated Expenses spiked by 58.75% in 2020 and then plummeted by 63.58% in 2021.
  • Quarterly analysis of 5 years shows Allogene Therapeutics' Other Accumulated Expenses stood at $4.8 million in 2020, then slumped by 63.58% to $1.7 million in 2021, then grew by 21.38% to $2.1 million in 2022, then declined by 14.59% to $1.8 million in 2023, then crashed by 40.74% to $1.1 million in 2024.
  • Its last three reported values are $1.1 million in Q4 2024, $1.8 million for Q4 2023, and $2.1 million during Q4 2022.